Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well giving bevacizumab together with lenalidomide and
dexamethasone works in treating patients with relapsed or refractory stage II or stage III
multiple myeloma. Monoclonal antibodies, such as bevacizumab, can block cancer growth in
different ways. Some block the ability of cancer cells to grow and spread. Others find cancer
cells and help kill them or carry cancer-killing substances to them. Bevacizumab and
lenalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer.
Dexamethasone may stimulate the immune system in different ways and stop cancer cells from
growing. Giving bevacizumab together with lenalidomide and dexamethasone may kill more cancer
cells.